The results implied that a combination of anti-C1q with anti-dsDNA antibodies and/or serum levels of C3 and C4 could significantly increase the specificity but decrease the sensitivity for identification of patients with active SLE diseases and LN in comparison with the use of each of these markers alone. Here, C3 is linked to lobular neoplasia.